OBP 801

Drug Profile

OBP 801

Alternative Names: OBP-801; YM 753

Latest Information Update: 16 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Oncolys BioPharma
  • Class Cyclic peptides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Renal cancer
  • Discontinued Haematological malignancies; Mesothelioma; Pancreatic cancer

Most Recent Events

  • 16 Apr 2015 Discontinued - Preclinical for Haematological malignancies in Japan (unspecified route)
  • 16 Apr 2015 Discontinued - Preclinical for Mesothelioma in Japan (unspecified route)
  • 16 Apr 2015 Discontinued - Preclinical for Pancreatic cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top